Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study-Reference-Cited by-同舟云学术

Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

Published:2020-12-29 Issue:1 Volume:21 Page:87-96
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Menter Alan¹^ORCID,Arenberger Petr²,Balser Sigrid³,Beissert Stefan⁴,Cauthen Ashley⁵,Czeloth Niklas⁶,Soung Jennifer⁷,Jazayeri Sasha⁸,Weisenseel Peter⁹,Jayadeva Girish⁶

Affiliation:

1. Institute for Rehabilitation, Baylor Scott & White, Dallas, TX, USA

2. Department of Dermatology and Venereology, University Hospital Kralovske Vinohrady, Prague, Czech Republic

3. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

4. Department of Dermatology, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany

5. Renstar Medical Research, Ocala, FL, USA

6. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

7. Southern California Dermatology Inc., Santa Ana, CA, USA

8. Alliance Dermatology and Mohs Center PC, Phoenix, AZ, USA

9. TFS GmbH, Hamburg, Germany

Funder

Boehringer Ingelheim